GSK plc Sponsored ADR (GSK)
GSK enjoys success with mRNA flu vaccine trial
GSK PLC (LSE:GSK, NYSE:GSK) has been encouraged by the initial results of a seasonal flu vaccine using mRNA technology. Following disappointing tests for its vaccine division earlier in the week with trials of an experimental herpes treatment, the FTSE 100 pharmaceutical group said a phase II influenza vaccine has shown enough positive effects to be moved to final phase III trials.
GSK's mRNA flu vaccine programme to proceed to late-stage trials
British drugmaker GSK on Thursday announced positive results from its mid-stage trial of its seasonal influenza vaccine programme using the messenger RNA (mRNA) technology, saying it would now progress to late-stage clinical development.
GSK 'clouds' blowing over suggests Berenberg
GSK PLC (LSE:GSK, NYSE:GSK) has been reiterated as a 'buy' at broker Berenberg, which sees some of the ‘clouds of doubt' that have plagued the pharma group's summer starting to ease. Zantac litigation in Delaware has been the main drag says the broker, but changes to US recommendations for Arexvy have also been a worry.
GSK herpes vaccine fails in clinical trial
Shares in GSK PLC (LSE:GSK, NYSE:GSK) fell over 1% after the drug maker said it would abandon further trials for a potential herpes vaccine after disappointing results from its clinical trials so far. The FTSE 100 group said data from the phase II part of a proof-of-concept study of the vaccine candidate showed the drug, known as GSK3943104, showed it "did not meet the study's primary efficacy objective".
GSK's experimental HSV vaccine fails to meet main goal in trial
British drugmaker GSK said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main goal of a mid-stage trial and would not be taken forward to a late-stage trial.
GSK's Respiratory Drug Nucala Meets Goal in COPD Study
GSK announces positive data from a phase III study of Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD).
GSK drug promotes ‘significant and clinically meaningful reduction' in asthma symptoms
British pharmaceuticals giant GSK PLC (LSE:GSK, NYSE:GSK) has presented late-breaking data at the European Respiratory Society (ERS) International Congress, highlighting a 54% reduction in severe asthma exacerbations in patients treated with depemokimab. The findings are based on the Phase III AReS study, which focused on patients with eosinophilic asthma.
GSK sees positive COPD trial results
GSK PLC (LSE:GSK, NYSE:GSK) announced positive results from a Phase III clinical trial, MATINEE, evaluating Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD). The trial met its primary endpoint by demonstrating a statistically significant reduction in the annualized rate of moderate to severe exacerbations in patients treated with Nucala compared to a placebo.
GSK's asthma drug Nucala meets main goal in smoker's lungs trial
British drugmaker GSK on Friday announced positive results from its late-stage trial of asthma drug Nucala in treating chronic obstructive pulmonary disease (COPD), also known as smoker's lungs.
Why Is Glaxo (GSK) Up 10.3% Since Last Earnings Report?
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock?
GSK's RSV Vaccine Arexvy Gets EU Nod for Adults Aged 50-59 Years
The European Commission approves GSK's RSV vaccine, Arexvy, for use in adults aged 50-59 years with increased risk of the disease.
GSK Stock Gains 18.5% Year to Date: Time to Buy, Sell or Hold?
GSK's cheap valuation, reasonable stock price appreciation and bright growth potential indicate that investors should stay invested.
